Lemus replaces Lapointe as Sigma-Tau COO
This article was originally published in Scrip
Rare diseases company Sigma-Tau has appointed Dave Lemus chief operating officer, following the resignation of former COO Gregg Lapointe. Mr Lemus previously served as chief financial officer of MorphoSys, where he launched Germany's first ever biotech IPO in 1999. Prior to this, he worked in a variety of senior management roles at Roche and Lindt. He is currently chair of the board of Proteros, and a non-executive member of Axela's board.